Virus-associated ribozymes and nano carriers against COVID-19

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a zoo tonic, highly pathogenic virus. The new type of coronavirus with contagious nature spread from Wuhan (China) to the whole world in a very short time and caused the new coronavirus disease (COVID-19). COVID-19 has turned into a global public health crisis due to spreading by close person-to-person contact with high transmission capacity. Thus, research about the treatment of the damages caused by the virus or prevention from infection increases everyday. Besides, there is still no approved and definitive, standardized treatment for COVID-19. However, this disaster experienced by human beings has made us realize the significance of having a system ready for use to prevent humanity from viral attacks without wasting time. As is known, nanocarriers can be targeted to the desired cells in vitro and in vivo. The nano-carrier system targeting a specific protein, containing the enzyme inhibiting the action of the virus can be developed. The system can be used by simple modifications when we encounter another virus epidemic in the future. In this review, we present a potential treatment method consisting of a nanoparticle-ribozyme conjugate, targeting ACE-2 receptors by reviewing the virus-associated ribozymes, their structures, types and working mechanisms.

An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection

“…The ribozyme-based antiviral strategy involves ribozymes, which are RNA molecules with catalytic activity. This approach to antiviral therapy offers several potential advantages over other strategies, including specificity, reduced toxicity and the ability to target multiple sites on the viral RNA [ 70 ]. Ribozymes-based antiviral strategies involve the delivery of ribozymes to infected cells through exogenous delivery or endogenous delivery.…”

Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance

“…Second, synthesizing and classifying specific ribozymes against SARS-CoV-2 RNA gene loci is possible through a bioinformatics software application. As a result, nanocarriers containing ribozymes could be a significant means of RNA-based pharmaceutical methods in future implementations against SARS-CoV-2 [106] .…”

Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders

“…ASOs are being developed to target the mutated enzymes and proteins and either suppress them or cause their degeneration. RNA interference, CRISPR are underway for those with mutations of SOD1 gene, expansion of ATXN2 trinucleotide, repeat expansions of C9orf72 hexanucleotide, and FUS mutations ( Amado and Davidson, 2021 ; Dönmüş 2021 ). Huntington’s disease is caused due to CAG repeat sequence in Huntington’s gene.…”